Paul J. Hesketh MD
Chair, Lahey Health Cancer Institute and Professor, Medicine, Tufts Medical Center
Join to View Full Profile
Mall Rd# 41Burlington, MA 01805
Phone+1 781-744-8400
Fax+1 781-744-5245
Dr. Hesketh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified oncologist and Chair of Lahey Health Cancer Institute in Burlington, Massachusetts.
Education & Training
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1983
St Elizabeth's Medical CenterResidency, Internal Medicine, 1978 - 1981
Uconn School Of MedicineClass of 1978
Certifications & Licensure
FL State Medical License 2025 - Present
MA State Medical License 1980 - 2027
NH State Medical License 2024 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2001 Nov 01
- S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
- S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
Publications & Presentations
PubMed
- Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer.Mostafa Aglan, Erin Spyropoulous, Joel Oster, Paul J Hesketh, A J Piper-Vallillo
Respiratory Medicine Case Reports. 2025-01-01 - 19 citationsEmetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport
Supportive Care in Cancer. 2023-12-22 - 24 citations2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.Florian Scotté, Lee Schwartzberg, Hirotoshi Iihara, Matti Aapro, Richard Gralla
Supportive Care in Cancer. 2023-12-20
Other
- Characteristics of antiemetic drugsHesketh PJ, Longstreth GF
http://www.uptodate.com/contents/characteristics-of-antiemetic-drugs
UpToDate, Wolters Kluwer Health - 2013-02-18 - Pathophysiology and prediction of chemotherapy-induced nausea and vomitingHesketh PJ
http://www.uptodate.com/contents/pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-v
UpToDate, Wolters Kluwer Health - 2012-10-01 - Prevention and treatment of chemotherapy-induced nausea and vomitingHesketh PJ
http://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomitin
UpToDate, Wolters Kluwer Health - 2013-03-08
Press Mentions
Cancer Survivorship Program Goes the Extra MileJuly 18th, 2019
Management of Chemotherapy-Induced Nausea & VomitingDecember 10th, 2017- How to Succeed in Modernizing Clinical TrialsJanuary 10th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
